Close

FibroGen (FGEN) PT Raised to $80 at Stifel; Pamrevlumab Looks Active in IPF

August 8, 2017 6:25 AM EDT Send to a Friend
Stifel raised its price target on FibroGen (NASDAQ: FGEN) to $80.00 (from $38.00) while maintaining a Buy rating after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login